Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X6QL
|
|||
| Former ID |
DIB018014
|
|||
| Drug Name |
KGP94
|
|||
| Synonyms |
CHEMBL1269632; BDBM50330030
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coagulation defect [ICD-11: 3B10.0; ICD-10: I80-I82] | Clinical trial | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12BrN3OS
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)O)C(=NNC(=S)N)C2=CC(=CC=C2)Br
|
|||
| InChI |
1S/C14H12BrN3OS/c15-11-5-1-3-9(7-11)13(17-18-14(16)20)10-4-2-6-12(19)8-10/h1-8,19H,(H3,16,18,20)/b17-13+
|
|||
| InChIKey |
ZDBKSZKTCPOBFR-GHRIWEEISA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin L (CTSL) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Collagen degradation | ||||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6533). | |||
| REF 2 | Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.